

**Supplementary Table 2** Summary of Patient Characteristics

Patient	CD4 <sup>+</sup> T Cell Count at Study Entry (Cells/ $\mu$ L)	Plasma HIV RNA at Study Entry (copies/mL) <sup>a</sup>	HAART Regimen at Study Entry <sup>b</sup>	Duration of Treatment (Years)
1 <sup>c</sup>	1220	<50	AZT, 3TC, SQV, LPV/r	9.1
2 <sup>c</sup>	516	<50	ABC, TDF, NVP	8.3
4 <sup>c</sup>	330	<50	AZT, 3TC, NFV	7.6
5 <sup>c</sup>	610	<50	ABC, 3TC, NVP	8.1
7 <sup>c</sup>	520	<50	3TC, TDF, EFV, LPV/r	8.0
8 <sup>c</sup>	662	<50	AZT, 3TC, EFV	8.6
J2 <sup>d</sup>	574	<50	ABV, TDF, NVP	9.9
J7 <sup>d</sup>	371	<50	AZT, 3TC, LPV/r	7.1
182 <sup>e</sup>	1101	<50	ABV, 3TC, EFV	6.3
202 <sup>e</sup>	618	<50	SQV, LPV/r, ENF	6
206 <sup>e</sup>	724	<50	FTC, TFV, AZV/r	6.4
209 <sup>e</sup>	428	<50	3TC, AZT, IDV, TFV	5.9
99 <sup>f</sup>	451	<50	d4T, 3TC, TDF LPV	1.3 <sup>g</sup>
113 <sup>f</sup>	306	<50	3TC, ABV, NFV	3.0 <sup>g</sup>
134 <sup>f</sup>	394	<50	3TC, TDF, EFV	0.9 <sup>g</sup>
135 <sup>f</sup>	445	<50	AZT, 3TC, SQV, RTV	6.6 <sup>g</sup>
136 <sup>f</sup>	696	<50	AZT, 3TC, EFV	3.3 <sup>g</sup>
139 <sup>f</sup>	475	<50	EFV, APV, LPV	2.8 <sup>g</sup>
147 <sup>f</sup>	502	<50	TDF, EFV, SQV, RTV	0.9 <sup>g</sup>
148 <sup>f</sup>	670	<50	ddl, NVP, LPV	2.9 <sup>g</sup>
154 <sup>f</sup>	167	<50	AZT, 3TC, ABC, TDF, LPV	1.4 <sup>g</sup>

<sup>a</sup>HIV RNA measured by Roche Amplicor Monitor version 1.5, with a detection limit of 50 copies of HIV RNA per mL of plasma.

<sup>b</sup>Drugs used in the various HAART regimens included zidovudine (AZT), abacavir (ABC), lamivudine (3TC), tenofovir (TDF), efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r), ritonavir (RTV), nelfinavir (NFV), saquinavir (SQV), enfuvirtide (ENF), atazanavir/ritonavir (AZV,r), emtricitabine (FTC), tenofovir (TFV), indinavir (IDV), stavudine (d4T), lopinavir (LPV), abacavir (ABV), amprenavir (APV), and didanosine (ddl).

<sup>c</sup>Patient sequences derived from Chun *et al.* (10).

<sup>d</sup>Patient sequences derived from Chun *et al.* (11).

<sup>e</sup>New patients analyzed for this study.

<sup>f</sup>Patient sequences derived from Bailey *et al.* (1).

<sup>g</sup>Duration of current regimen only.